|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The prognostic significance of tumour tissue CD26 expression levels was assessed by univariate and multivariate analyses.
|
24870408 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells.
|
10645005 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with the DPP-4 inhibitor KR62436 (KR) promoted primary tumor growth and lung metastasis in a 4T1 tumor allograft mouse model; DPP-4 knockdown in 4T1 cells displayed similar phenotypes <i>in vivo</i> and <i>in vitro</i>.
|
30584072 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl peptidase 4 (DPP4) is a cell surface protein that can act as a tumor suppressor or activator, depending upon the level of expression and interaction with the microenvironment and chemokines.
|
31124302 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that tumor-associated stroma involving α-SMA-positive myofibroblasts stained negative or negligible for CD26 in 118 out of 193 (61.1%) tumors, whereas noncancerous stromal regions of the breast showed considerable staining for CD26.
|
31140748 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a subcutaneous murine model treated with paclitaxel, on Day 39, the tumor size of the DPPIV-transfected cell-inoculated group was as large as that of the vector-transfected cell-inoculated group.
|
19917055 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover patients with HER2 positive tumors had significantly lower CD26 serum levels (511.8 ± 84.8 pg/mL) compared with HER2 negative tumors (619.1 ± 109.9 pg/mL, p = 0.006).
|
26471376 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DPPIV/CD26 and SerpinB3 were localized in the same tumoral areas and both molecules were correlated with the grade of tumor differentiation, with the highest values detected in GI tumors.
|
29524519 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Neutral endopeptidase (NEP/CD10) and dipeptidyl peptidase IV (DPP IV/CD26) are both ubiquitous glycopeptidases which play important roles in tumor pathogenesis and development.
|
23686701 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, soluble DPP IV activity positively correlated with the aggressiveness of CCRCCs (higher activities in high grade tumors).
|
20459800 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A higher expression of CD26/DPP4 is found in a wide variety of tumor entities, however more research on CD26/DPP4 in the tumor microenvironment is needed to fully explore its use as a tumor biomarker.
|
30822465 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, DPPIV functions as a tumor suppressor, and its downregulation may contribute to the loss of growth control in NSCLC cells.
|
15027119 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD26, a 110-kDa transmembrane glycoprotein with known dipeptidyl peptidase IV activity, plays a role in tumor development and its expression was reported in various human malignancies.
|
21894438 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Based on our results, it can be concluded that, (1) as opposed to activated or reactive normal T cells, the expression of CD26 and of CD40L is mutually exclusive in human T-cell lymphomas/leukemias; (2) expression of CD26 is restricted to aggressive pathologic entities, such as T-cell LBL/ALL and T-cell CD30+ ALC lymphomas, whereas CD40L is expressed on slow progressing diseases such as mycosis fungoides; and (3) within the T-cell LBL/ALL group of tumors, CD26 may identify a subset of poor prognosis patients.
|
8541553 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings provide insight into IL-33- and eosinophil-mediated tumor control, revealed when endogenous mechanisms of DPP4 immunoregulation are inhibited.
|
30778250 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast activation protein alpha (FAP-α) and dipeptidyl peptidase IV (DPPIV) are proteases located at the plasma membrane promoting cell invasiveness and tumor growth and have been previously associated with keloid scars.
|
20872224 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High CD26 expression in the stroma, but not the tumor itself, was significantly correlated with a poor prognosis.
|
26370256 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Orthotopic HT-29 xenografts treated with standard CRC chemotherapeutics 5-fluorouracil, irinotecan, or oxaliplatin showed dramatic increases in CD26 compared to untreated tumors.
|
26552750 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This screening method enables us to develop novel anti-human CD26 mAbs suitable for immunohistochemical staining of CD26 in FFPE non-tumor and tumor tissue sections with reliable clarity and intensity.
|
31194830 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl peptidase IV (DPPIV) is a serine protease with tumor suppressor function.
|
15735018 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these results implicate DPP4 as an AR-regulated tumor suppressor gene whose loss enhances growth factor activity and suggest that treatment with DPP4 inhibitors may accelerate emergence of resistance to ADT.<b>Significance:</b> These findings identify DPP4 as an AR-stimulated tumor suppressor gene that is downregulated during progression to castration-resistant prostate cancer, warning that treatment with DPP4 inhibitors, commonly used to treat type 2 diabetes, may accelerate prostate cancer progression following androgen deprivation therapy.<i></i>.
|
30242112 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of glucagon-like peptide-1 receptor and dipeptidyl peptidase-IV in neuroendocrine neoplasms of the pancreas and gastrointestinal tract.
|
25119061 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Microarray analysis of glioma cells with forced DPP-IV expression revealed differential expression of several candidate genes not linked to the tumor suppressive effects of DPP-IV in previous studies.
|
22306301 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, silencing lncRNA-OIS1 diminished the senescent-associated induction of a nearby gene (Dipeptidyl Peptidase 4, DPP4) with established role in tumor suppression.
|
29481642 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DPP-IV enzymatic activity increased dramatically with tumour grade severity.
|
17786309 |
2007 |